Federal Health Grants

The "Enhancing Biomedical Engineering, Imaging, and Technology Acceleration (BEITA) at Historically Black Colleges and Universities (HBCUs)" grant aims to develop and improve biomedical engineering departments, technology centers, and academic programs at HBCUs, with a focus on supporting research, education, faculty recruitment, curriculum development, and innovation programs.

The purpose of this Funding Opportunity Announcement (FOA) is to correlate immune system development patterns between two or more age groups - neonates, infants, and children and adolescents and further understand the impact of infectious diseases, microbiome and environmental factors on the ontogeny and development of the pediatric immune system, from birth, transitioning into adolescence and adulthood with the focus of impact during pregnancy and post-natal period.Purpose The purpose of this Funding Opportunity Announcement (FOA) is to correlate immune system in general and development patterns in particular, between two or more age groups - neonates, infants, and children and adolescents and further understand the impact of infectious diseases, microbiome and environmental factors on the ontogeny and development of the pediatric immune system, from birth, transitioning into adolescence and adulthood with the focus of impact during pregnancy and post-natal period. Background Worldwide, mortality in children under the age of 5 is predominantly due to infectious diseases and immune modulations associated with these infections. Pediatric immune system is remarkably different from adult immune system and also forms the basis for overall wellbeing and providing an adequate disease encountering status to adulthood. A protected and systematically trained pediatric immune system results in a robust and efficient adult immune system. Moreover, immune system in children responds strongly, rapidly and robustly in comparison to adult immune system to immunization, diet and environmental factors. Knowledge of development of the pediatric immune system in response to exposure to childhood infections and vaccinations, microbiome and the environmental factors can help chart pathways that provide strategies to prevent and treat infectious diseases more efficiently. These variations between pediatric and adult immune systems offer insight into better understanding strategies for developing immune-therapeutics and vaccines against infections. The research focus in the current announcement is multi-disciplinary. The focus however is in the areas of immune ontogeny and development, the mechanisms of infant and neonatal immunity or relationship between ontogeny of immunosuppression, susceptibility to infection during infancy or studies on effect of early infections or vaccinations that train the immune system. It is expected to diversify areas in existing research and draw comparisons between age groups or specific organ system development (for example, projects of interest might investigate immune cell ontogeny in lung alveoli from infancy to adult hood or immune alterations due to exposure to a specific immunogen (like measles or BCG vaccine) at infancy vs adolescence and the chronic effect of air pollution). More specifically, the aim here is to elucidate immune system development patterns in infants, children and adolescents focusing on both the innate immunity and the development of diverse antibodies or T cell maturation, with relevance to chronic infections (not limited to HIV, CMV, TB and the current SARS-CoV2 pandemic as well). Further, the intention is to expand the science to include additional internal factors like microbial metabolites and/or external factors like the environment that modulate the developing immune system so that a research program that is multi-disciplinary can be developed to address the interaction between host and pathogen. Research Scope The over-arching scope of this FOA is: to correlate immune system in general and development patterns in particular, between two or more age groups - neonates, infants, and children and adolescents to understand the evolution or immune ontogeny in human immune system development focusing on either or both, innate and adaptive immune systems with additional focus on internal factors like the microbiome and/or external factors like the environment. Further, the scope can be covered under these following topics and is not limited to: Study in young children vs adolescents vs adults, development of immunity and variations in immune system in physiology and in response to infectious diseases focusing on MTCT diseases (HIV, CMV, TB, Syphilis, SARS-CoV2 etc.), not limited to, broadly neutralizing antibodies (bNAbs), development of mucosal antibodies, germinal center formation and maturation; correlate with T cell development and identification of immunogens that activate T cells without enhancing infection. Characterize the impact of age, environmental factors, microbial metabolites and microbiome composition in relation to the immune responses against acute or chronic infectious diseases not limited to HIV, TB, CMV, SARS-CoV2 etc., and their contribution towards the development of a robust immune system development using novel technologies (RNA seq, imaging of immunogens and cellular interactions, single cell imaging). Understand cellular and soluble immune system components and the developmental pathways, including the microbiome, that regulate these components in specific age-groups. For example, developing immune profiles of HIV exposed un-infected (HEU) infants in comparison with the immune profile of an adolescent living with HIV and how these immune alterations prepare the immune system to encounter future infections. Study the contribution of increased exposure to environmental factors, pathogens, extensive or scheduled immunization early in life on enhanced cross-talk between innate and adaptive immune systems; specific inflammatory responses generated by innate immune factors and their downstream effect on cellular immune development. Delineate the role of human microbiome in health and disease and the environmental factors to observe correlation of immune responses against acute and chronic infections and focus on transfer of microbes and immune factors from human milk to infants. For example, assess alterations in immune profiles of known oral microbial clusters in CMV infected child vs immune profiles in an adolescent. Understand the impact of variations of microbiome in specific organ systems (gut vs oral vs vaginal microbiomes) in age defined profiles and their effect on immune ontogeny with emphasis on Virome . Influence of maternal microbiome on the effect of microbial composition and development of immunity in the offspring; detailed studies exploring placental microbiome and correlation with maternal oral microbial microbiome are encouraged. Projects that will be considered non-responsive for this FOA include, but are not limited to: Applications proposing vaccine advocacy. Applications proposing to focus exclusively on effects of microbiome and not studying the relevance of these effects on immune system development. Applications proposing to focus exclusively on epigenomic approaches. Applications focusing on immunization strategies in infants for altering early immune responses.

This grant provides funding for research projects aimed at improving the diagnosis and treatment of health conditions related to the September 11, 2001, terrorist attacks, specifically for individuals who were exposed in New York City and surrounding areas.

This funding opportunity provides financial support to states and organizations for developing a coordinated care model that improves health services for children with serious, long-term medical conditions.

This grant provides funding to strengthen the management and evaluation of human resources in Malawi's national HIV and TB programs, focusing on hiring skilled personnel to support epidemic control efforts.

The purpose of the USAID Usalama ya Afya Duniani activity is to support the strengthening of Tanzanias capacities to develop, validate, and implement interventions to prevent, detect, and respond to EID threats in Tanzania using a One Health approach.The United States Agency for International Development (USAID) Mission in Dar es Salaam, Tanzania is publishing this Request for Information (RFI) to obtain information and inputs from all capable and interested entities for the anticipated USAID Usalama wa Afya Duniani activity. This activity is designed to identify and implement proven, collaborative, and evidence-based Global Health Security approaches in Tanzania, in support of strengthening the country’s capabilities to prevent, detect and respond to emerging infectious disease outbreaks.

Dear Interested Applicants:This Annual Program Statement (APS) publicizes in accordance with ADS 303.3.5.2(b) as the intention of the United States Government (USG), as represented by the United States Agency for International Development (USAID), Indonesia Mission, to fund one or multiple awards to improve the capacity of the National Tuberculosis Program, local partners, and communities to effectively detect, diagnose, and treat people affected by tuberculosis and provide preventive services to all people in need, while building a sustainable and resilient health system in Indonesia.This document is an umbrella APS that is not calling for any submission and will not solicit any concept papers nor applications. Prospective applicants will be provided a fair opportunity to develop and submit competitive applications to USAID for potential funding via APS Addendums under this APS. USAID Indonesia intends to make several assistance awards with US and local NGOs to assist the Government of Indonesia (GOI) in accelerating achievement toward its 2030 TB elimination.Following this APS, USAID will issue APS Addendum(s) with more detailed information for applicants to submit their applications. USAID Indonesia may utilize co-creation with prospective applicants during various stages of APS Addendum procurements and applicants may be invited to participate in virtual or in-person events. If/when there is any change related to this APS, the mission will amend this APS accordingly.Issuance of this APS does not commit USAID to make any awards nor to pay for the costs incurred in the preparation and submission of an application. USAID also reserves the right to reject any application received in response to the APS Addendum(s). USAID reserves the right not to conduct a co-creation and request Full Applications from successful applicants at the concept paper stage, or to conduct co-creation at a later stage of the process. The actual number of awards under this APS is subject to the availability of funds and the viability of applications received. USAID also reserves the right to award multiple awards or no awards at all through this APS.This APS and the APS Addendum will be posted on www.sam.gov and www.grants.gov. It is the responsibility of the Applicant to regularly check both websites to ensure they have the latest information pertaining to this APS and to ensure that the APS has been received from the internet in its entirety. USAID bears no responsibility for any data errors resulting from transmission or conversion process. If you have difficulty registering on www.grants.gov or accessing the APS document, please contact the Grants.gov Helpdesk at 1-800-518-4726 or via email at support@grants.gov for technical assistance.Thank you for your interest in USAID programs.

The "Facilitating Preclinical and Early Phase Human Studies for New Therapeutics" grant aims to fund research that advances new treatments from preclinical stages to first-in-human trials for aging-related conditions, excluding neurodegenerative and Alzheimer's diseases, with a focus on improving injury repair in older adults and defining clear milestones for progress monitoring.

This grant provides funding to early-stage researchers exploring innovative chemical and pharmacological approaches to understanding and treating substance use disorders.

This funding opportunity provides financial support to accredited residency programs in primary care to enhance training in street medicine, focusing on delivering comprehensive healthcare to individuals experiencing homelessness.

The purpose of this Planning Cooperative Agreement is to provide resources to Tribes interested in entering the Tribal Self-Governance Program (TSGP) and to existing Self Governance Tribes interested in assuming new or expanded PSFAs. Title V of the Indian Self-Determination and Education Assistance Act (ISDEAA) requires a Tribe or Tribal organization (T/TO) to complete a planning phase to the satisfaction of the Tribe. The planning phase must include legal and budgetary research and internal Tribal government planning and organizational preparation relating to the administration of health care programs.The planning phase is critical to negotiations and helps Tribes make informed decisions about which Programs, Services, Functions, and Activities (PSFAs to assume and what organizational changes or modifications are necessary to successfully support those PSFAs. A thorough planning phase improves timeliness and efficient negotiations and ensures that the Tribe is fully prepared to assume the transfer of IHS PSFAs to the Tribal health program.A Planning Cooperative Agreement is not a prerequisite to enter the TSGP and a Tribe may use other resources to meet the planning requirement. Tribes that receive Planning Cooperative Agreements are not obligated to participate in the TSGP and may choose to delay or decline participation based on the outcome of their planning activities. This also applies to existing Self Governance Tribes exploring the option to expand their current PSFAs or assume additional PSFAs.

The STRIPE program grant is designed to fund pre-clinical research that explores how radiopharmaceutical therapy affects cancer cells and their environment, with the aim of developing new targeting strategies and informing the design of future RPT-based clinical trials.

This funding opportunity supports innovative interventions to improve the health and quality of life for people living with HIV, particularly those from racial and ethnic minority populations and low-income backgrounds, by addressing related health issues and promoting successful aging.

This grant provides funding to U.S. small businesses for research and development projects that aim to advance health-related technologies and facilitate their commercialization.

This funding opportunity supports innovative research projects aimed at improving mental health services and addressing disparities in access and quality, particularly for underserved populations.

This funding opportunity provides financial support to community coalitions focused on preventing youth substance use by fostering collaboration among various local stakeholders.

This funding opportunity provides financial support to small businesses with active Phase I SBIR or STTR grants from NIH or CDC, helping them accelerate the commercialization of biomedical and public health innovations through training and market research.

The purpose of the PPC program is to provide interdisciplinary training to improve the health of infants, children, and adolescents with chronic respiratory conditions, sleep issues, and other related special health care needs.

To establish a Data Center to coordinate and analyze single cell and other molecular data sets generated by Single Cell Opioid Responses in the Context of HIV (SCORCH) and other NIDA-funded HIV and substance use disorder projects and to make the data findable, accessible, interoperable, and reusable (FAIR) to enable secondary analyses by the scientific community. This is a non-competitive funding opportunity intended to fund a single award. The National Institute on Drug Abuse (NIDA) is announcing its intent to issue a single source cooperative agreement award to the University of Maryland Baltimore to 1. Coordinate all the data generated by the SCORCH consortium, 2. Analyze all the data generated by the SCORCH consortium, 3. Perform necessary SCORCH program scientific outreach activities, and 4. Support SCORCH consortium communication. The current SCORCH Data Center is integrated with the rest of the SCORCH consortium and is familiar with the current data, metadata, and data quality metric standards and data pipelines. They were involved in establishing these standards and have been/are working closely with key personnel on SCORCH data generation projects to ensure data and associated metadata are deposited. Continued support of the University of Maryland Baltimore SCORCH Data Center to complete the SCORCH Program activities will enable seamless SCORCH data coordination and archiving, will prevent disruption in data analysis, and will allow continued support of the currently existing SCORCH website which is the scientific face of the SCORCH program. Background Single Nucleus Assays: Molecular analysis of brain tissue typically relies on ensemble averaging of heterogenous mixtures of cell types within a specific brain region. However, technological advances enable molecular characterization of large numbers of individual cells. Single cell approaches can uncover effects on rarer cell types and have the potential to reveal cellular differences resulting from specific niche environments or transitory cellular states. Some single cell technologies in use include single cell RNA-sequencing (scRNA-seq), single nucleus RNA-sequencing (snRNA-seq), single nucleus assay for transposase-accessible chromatin-sequencing (snATAC-seq), single cell Hi-C, and spatial genomics approaches such as multiplexed fluorescence in situ hybridization (FISH). Individual researchers as well as large project teams including the Human Cell Atlas, Common Fund Human BioMolecular Atlas Program (HuBMAP), and NIH BRAIN Initiative Cell Atlas Network (BICAN) are exploiting these technologies to understand the diversity of cell types within the human body as well as their functions in human health and disease. Addictive Substances. Chronic exposure to addictive substances can lead to long term changes in brain function and to substance use disorders (SUDs). Many known brain regions are involved in addictive processes including the prefrontal cortex, nucleus accumbens, ventral tegmental area, striatum, insula, amygdala, and hippocampus. Despite great advances in our understanding of molecular pathways and circuits involved in SUDs, there remains limited knowledge concerning 1. The specific types, numbers, and gene expression profiles of cells within these brain regions and 2. How exposures to addictive substances influence the states and functions of these cells. HIV/ART. Antiretroviral therapy (ART) has, in large part, transformed the HIV epidemic into a chronic manageable disease in the United States. However, people living with HIV remain at higher risk for impaired cognitive functions (e.g. HIV-Associated Neurocognitive Disorder [HAND]). Use of addictive substances by HIV-infected individuals has the potential to further alter immune function and/or exacerbate HIV-related CNS impairment. However, little is known about 1. The effects of persistent HIV infection or HIV treatment regimens on gene expression in specific CNS cell types in key brain regions, or 2. How chronic addictive substance use might modify these effects. SCORCH. The Single Cell Opioid Responses in the Context of HIV (SCORCH) consortium was formed to begin to address scientific questions about addiction and HIV/ART questions at the single cell level. Fifteen funded SCORCH data generation projects (NIDA SCORCH Program) have been generating brain snRNA-seq or snATAC-seq data. Four brain types are being assayed by all groups: control, drug-exposed/SUD, HIV+, and HIV+drug exposed/SUD. Emphasis is on individuals with chronic exposure to opioids, cocaine, methamphetamine, or cannabinoids. Four groups are generating data from non-human primate brain, four from rodent brain, and nine from human post-mortem brain with some data from human organoids as well. The SCORCH data coordination, analysis, and scientific outreach center was established to standardize and share the single cell molecular HIV/SUD data generated by this program by ensuring that the data is FAIR (Findable, Accessible, Interoperable, and Reusable). Harmonized molecular and single cell HIV/SUD data sets will enable data mining by the scientific community to uncover new HIV and/or SUD mechanisms and to identify candidate pathways for therapeutic intervention. The SCORCH Data Center will also enable future mining of these data sets as improved data science and information technology approaches are developed, maximizing NIDA ’s original investment in the data generating activities. Scope. The proposed project should be framed to answer one or more vexing questions about persistent HIV infection in the brain. In addition, the major thrust of the proposed project MUST: Propose to coordinate and analyze single cell and other molecular data sets generated by SCORCH and other NIDA-funded HIV and substance use disorder projects. Propose to make this data findable, accessible, interoperable, and reusable (FAIR) to enable secondary analyses by the scientific community. Applicants are encouraged to contact NIDA program staff to answer any questions. Key activities of the SCORCH Data Center will be to: Work with SCORCH consortium members to ensure that all data and metadata have standardized formats and associated quality metrics and have been processed through standardized pipelines. Associate new SCORCH data with clinical metadata from the appropriate brain banks or tissue sources. Work closely with the SCORCH consortium PD(s)/PI(s) to analyze the data generated, to develop analysis strategies to integrate the datasets in synergistic ways with other relevant datasets, and to share useful information and insights about these data with the broader biomedical research community. It is anticipated that the SCORCH Data Center will lead an integrative analysis of all the SCORCH single cell data in a capstone publication. Develop strategies to enable and improve coordination, analysis, and sharing of spatial genomics and related data types. Develop strategies to enable and improve coordination, analysis, and sharing of data types from spatially and/or functionally resolved cellular assemblies relevant to HIV or addiction. Examples include but are not limited to anatomical structures, functional networks and ensembles characterized under PAR-20-241/ RFA-DA-22-011/ RFA-DA-23-035 “Large Scale Integrated Mapping and Molecular Profiling of Cell Ensembles and/or Cell-Types Mediating Opioid Action in the Rodent Brain” and RFA-DA-23-036 “Investigating the Effects of Addictive Substances on Brain Developmental Trajectories Using Innovative Scalable Methods for Quantification of Cell Identity, Lineage and Connectivity.” Archive raw and processed datasets generated by the SCORCH consortium in appropriate NIH-supported archives. Maintain, and improve a website to serve as a community-wide nexus for SCORCH protocols, assay and data standards, raw and processed data, data pipelines, and other resources generated by the consortium. Facilitate SCORCH data use by the scientific community for data mining to identify candidates for SUD and/or HIV therapeutic targets or to investigate SUD or HIV mechanisms. Provide user-friendly access to consortium data and by identifying or generating robust tools to enable both naive and experienced investigators to query, integrate, analyze, and model the data. Develop workshops and implement a community outreach strategy to inform the research community of the accomplishments of the SCORCH program and disseminate information about the community resources and data generated by the program. Coordinate SCORCH consortium activities by organizing steering committee meetings, workgroup meetings, external program consultant logistics, and other awardee meetings as needed. Plan for Enhancing Diverse Perspectives : This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP) as described in NOT-MH-21-310, submitted as Other Project Information as an attachment (see Section IV). Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material. The PEDP will be assessed as part of the scientific and technical peer review evaluation, as well as considered among programmatic matters with respect to funding decisions.

This funding opportunity provides financial support for researchers and institutions to discover and develop new treatments for serious fungal infections that are difficult to treat due to resistance and safety issues.